Central to terminal exhaustion is the accumulation of defective mitochondria within T cells—organelles that conventionally act as bioenergetic hubs fueling cellular activity. Loss of mitochondrial integrity and function not only deprives T cells of necessary energy reserves but also orchestrates shifts in gene expression that anchor these cells in a dysfunctional, non-proliferative state. Despite recognition of this connection, the mechanistic link between mitochondrial damage and transcriptional reprogramming remained obscure until recently. A groundbreaking study spearheaded by Yingxi Xu and Ping-Chih Ho at Ludwig Lausanne unveils the intricate molecular cascade connecting mitochondrial demise to T cell exhaustion, spotlighting the pivotal role of heme signaling.

This newly elucidated pathway identifies heme—a porphyrin ring-containing iron molecule historically noted for its role in oxygen transport—as a hitherto unrecognized agent facilitating T cell dysfunction. Typically embedded within mitochondrial proteins, heme becomes aberrantly released amidst mitochondrial degradation failures endemic to exhausted T cells in the TME. Xu and colleagues demonstrate that the proteasome, the cell’s principal protein degradation machinery, becomes hyperactivated under these conditions and preferentially dismantles mitochondrial heme-containing proteins. This selective degradation engenders an intracellular surge of free heme, which is subsequently converted into a distinct regulatory form.

The regulatory heme translocates into the nucleus via the transporter protein PGRMC2, where it exerts profound effects on gene expression by inducing degradation of a key transcription factor. This event triggers a cascade of molecular alterations culminating in the activation of exhaustion-associated genetic programs. Intriguingly, the researchers showed that genetic ablation of PGRMC2 interrupts this deleterious sequence, preserving T cells in a metabolically and functionally resilient state. Such findings highlight PGRMC2 as a promising therapeutic target for reinvigorating anti-tumor immunity.

Innovatively, this work also bridges these mechanistic insights to clinical immunotherapeutic strategies, particularly the chimeric antigen receptor (CAR) T cell therapy paradigm. CAR-T therapy, a transformative approach in cancer treatment whereby patient-derived T cells are engineered ex vivo to target cancer-specific antigens, often succumbs to similar exhaustion pathways post-infusion, limiting its long-term efficacy. Xu and Ho’s team employed a pharmacological intervention using bortezomib, a proteasome inhibitor conventionally approved for leukemia treatment, during the CAR-T cell manufacturing process. Remarkably, transient, low-dose administration of bortezomib curtailed exhaustion-associated transcriptional programs within CAR-T cells, fostering a durable intracellular milieu conducive to sustained proliferation and cytotoxic performance.

Clinical correlations further substantiated these preclinical observations. Analysis of CAR-T cells from B cell acute lymphoblastic leukemia (B-ALL) patients revealed that heightened proteasome activity within these cells portended poorer therapeutic outcomes, whereas diminished activity correlated strongly with complete remission and favorable prognoses. This underscores the potential for proteasome modulation as a biomarker and interventional target in enhancing CAR-T efficacy.

The study compellingly reframes T cell exhaustion, not merely as an irreversible endpoint of chronic antigenic stimulation, but as a reversible metabolic and signaling imbalance amenable to therapeutic correction. By dissecting the molecular interplay involving mitochondrial heme processing and proteasomal dynamics, this research provides a conceptual foundation for next-generation cellular immunotherapies aimed at reinvigorating T cell function. These approaches could substantially elevate the potency of immuno-oncology regimens, transforming resistant cancers into tractable diseases.

Furthermore, the implications of their findings extend beyond cancer, potentially influencing fields where T cell exhaustion is implicated, including chronic infections and autoimmune disorders. The integration of metabolic signaling pathways with gene regulation elucidates fundamental principles of immune cell biology that could inspire novel interventions across diverse therapeutic landscapes.

This pioneering investigation was underpinned by a vast network of support from numerous prestigious entities, including the Ludwig Institute for Cancer Research and the Swiss National Science Foundation, evidencing the collaborative efforts propelling advances in cancer immunology. The research outcomes published in Nature exemplify the power of molecular insights to unlock new horizons in immunotherapy.

In summary, Xu, Ho, and colleagues reveal that dysfunctional mitochondrial accumulation triggers a proteasome-dependent heme signaling axis, driving T cell exhaustion through transcriptional reprogramming mediated by regulatory heme and PGRMC2. This discovery not only unveils critical mechanistic underpinnings but also delineates actionable targets such as PGRMC2 and proteasome function modulation with existing drugs like bortezomib. These interventions promise to fortify the metabolic and functional fitness of tumor-targeting T cells, offering renewed hope for durable immune-mediated cancer control.

Subject of Research: Molecular mechanisms underlying T cell exhaustion in cancer and strategies to enhance immunotherapy

Article Title: Proteasome-guided haem signalling axis contributes to T cell exhaustion

News Publication Date: 18 March 2026

Web References:
https://www.nature.com/articles/s41586-026-10250-y

Image Credits: Ludwig Cancer Research

Keywords: T cell exhaustion, cancer immunotherapy, tumor microenvironment, mitochondrial dysfunction, heme signaling, proteasome, CAR-T therapy, PGRMC2, proteasome inhibition, bortezomib, metabolic reprogramming, transcriptional regulation

Central to T cell recognition of tumors are two primary classes of antigens. Tumor-specific neoantigens arise from somatic mutations unique to cancer cells, exhibiting high immunogenicity and minimal expression in normal tissues. Such neoantigens offer exquisite specificity, reducing the risk of off-tumor effects. Conversely, tumor-associated antigens, while not exclusive to malignant cells, are often overexpressed in tumors and serve as additional targets to mobilize T cell cytotoxicity. This dual targeting strategy underscores the complexity of immune surveillance within heterogeneous tumor ecosystems.

Despite the potent capabilities of T cells, tumors have evolved sophisticated mechanisms to evade immune detection and destruction. Among these, the induction of T cell exhaustion within the immunosuppressive tumor microenvironment (TME) significantly impairs the effector functions of infiltrating lymphocytes. This exhaustion is characterized by sustained expression of inhibitory receptors and diminished cytokine production, effectively blunting the anti-tumor immune response and fostering tumor progression under an immunologically suppressive milieu.

Moreover, tumors can undergo immunoediting, a dynamic process wherein cancer cells lose or alter their antigenic profiles to escape T cell recognition. This antigenic plasticity poses a substantial barrier to effective immunotherapy, necessitating strategies that address tumor heterogeneity and adaptability. Physical barriers within the TME, including aberrant vasculature and stromal components, further obstruct T cell infiltration and limit their capacity to exert cytotoxic effects at tumor sites.

Modern immunotherapeutic approaches leverage the diverse functionalities of T cells to circumvent tumor evasion. Antibody-based therapies, such as immune checkpoint inhibitors, alleviate inhibitory signals like PD-1/PD-L1 and CTLA-4 pathways, reinvigorating exhausted T cells. Bispecific T cell engagers (BiTEs) bridge T cells to tumor cells, facilitating direct cytotoxic engagement. These modalities have revolutionized treatment paradigms, achieving remarkable clinical responses in several cancer types.

Adoptive Cell Transfer (ACT) represents another therapeutic frontier in which autologous or allogeneic T cells are expanded or genetically engineered ex vivo and then infused back into patients. Tumor-Infiltrating Lymphocyte (TIL) therapy involves isolating and expanding naturally occurring tumor-specific T cells. Genetically modified therapies, including Chimeric Antigen Receptor (CAR) T cells and T Cell Receptor-engineered (TCR-T) cells, enhance recognition capabilities against specific tumor antigens, opening new avenues for hematologic and solid tumor treatment.

Cancer vaccines are designed to prime the immune system by presenting tumor antigens, inducing robust, antigen-specific T cell responses. These vaccines serve as both prophylactic and therapeutic tools, aiming to generate durable immunity against existing tumors or prevent tumor recurrence. Despite their promise, the immunosuppressive TME and antigenic variability continue to challenge vaccine efficacy in clinical contexts.

Professor Tao Dong emphasizes the necessity of combination therapies that integrate these distinct immunotherapeutic modalities. Such regimens are designed to conduct a multifaceted assault on cancer—overcoming antigen escape, reversing T cell exhaustion, and dismantling the physical and immunological barriers of the TME. The orchestration of these therapies holds the key to overcoming the limitations of monotherapies and improving patient outcomes comprehensively.

Cutting-edge research efforts are focused on two critical axes that could revolutionize T cell immunotherapy. First, the identification and cataloging of precise tumor antigens, alongside sophisticated T cell receptor (TCR) libraries, aim to tailor treatments uniquely suited to individual tumor antigen landscapes. Second, unraveling the nuanced biology of T cell subsets and their functional states promises to yield biomarkers for optimizing patient selection and predicting therapeutic responses, thus personalizing immunotherapy at an unprecedented scale.

This comprehensive understanding of T cell-mediated immunity and the multifarious avenues of immunotherapeutic intervention form a robust framework for pioneering more effective, resilient cancer treatments. Researchers and clinicians are poised to translate these insights into clinical success, addressing enduring challenges such as tumor heterogeneity, immune suppression, and therapy-induced toxicities.

As the field advances, technological innovations including single-cell omics and spatial transcriptomics are refining our ability to dissect T cell-tumor interactions in situ, providing granular insights into immune evasion and therapeutic resistance. These precision tools facilitate the rational design of next-generation immunotherapies, with the potential to unlock enduring remission and possibly cure for diverse malignancies.

In sum, leveraging T cells for cancer immunotherapy embodies a paradigm shift, harnessing the specificity, adaptability, and potency of adaptive immunity. The convergence of molecular understanding, engineering prowess, and clinical acumen heralds a new era in oncology—one where immune cells are not just defenders but powerful allies in the quest to conquer cancer.

Subject of Research: Not applicable

Article Title: Leveraging T cells for cancer immunotherapy

News Publication Date: 21-Oct-2025

References: DOI: 10.1007/s44466-025-00007-z

Image Credits: Professor Tao Dong Team, University of Oxford, Oxford, UK

Keywords: Cancer immunotherapy, T lymphocytes, Immunity, Tumor microenvironments, Antigens, Neoantigens, Cancer vaccines, Cancer treatments, Biomarkers, Cell biology